The US FDA has posted details, including company and FDA Briefing Materials, for the Wednesday, May 25, 2016 Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) meeting. The Committee will discuss the safety and efficacy of iGlarLixi (insulin glargine and lixisenatide injection) and Lyxumia (lixisenatide injection) by Sanofi Aventis c/o Sanofi U.S. Services Inc. (Sanofi), proposed for the treatment of adults with type 2 diabetes mellitus.

See the SAC Tracker report